NCT01508247已完成3 期
A Multiple-center Randomized Double-blind Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of an Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Aged 6-35 Months
Jiangsu Province Centers for Disease Control and Prevention4 个研究点 分布在 1 个国家目标入组 10,245 人开始时间: 2012年1月最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 10,245
- 试验地点
- 4
- 主要终点
- the incidence density of the EV71-associated diseases in the vaccine group and placebo group.
研究概览
简要总结
Since its discovery in 1969, enterovirus 71 (EV71) has been recognised as a frequent cause of epidemics of hand-foot-mouth disease (HFMD) associated with severe neurological sequelae in a small proportion of cases. There has been a significant increase in EV71 epidemic activity throughout the Asia-Pacific region since 1997. Recent HFMD epidemics in this region have heen associated with a severe from of brainstem encephalitis associated with pulmonary oedema and high case-fatality rates.
The data from the phase 1 and 2 trials suggested that the inactivated EV71 vaccine had a clinically acceptable safety and good immunogenicity for healthy Chinese children and infants. According to the immunogenicity and safety results, the 320U with adjuvant with immunizing schedule of two doses (per 28 day) will be applied in phase 3 clinical trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 6 Months 至 35 Months（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Only subjects fulfilling all of the following criteria will be eligible for the study:
- •Healthy children aged from 6 to 35 months old
- •General good health as established by medical history and physical examination
- •The subjects' guardians are able to understand and sign the informed consent
- •Had never received the vaccine against EV71
- •The subjects' guardians allow to comply with the requirements of the protocol
- •Available for all visits scheduled in this study
- •Subjects with temperature <=37.0°C on axillary setting
排除标准
- •Subjects will not be eligible for the study if any of the following criteria is met:
- •Subject who has a medical history of HFMD
- •Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine
- •Family history of seizures or progressive neurological disease
- •Family history of congenital or hereditary immunodeficiency
- •Severe malnutrition or hypogenesis
- •Major congenital defects or serious chronic illness, including perinatal brain damage
- •Autoimmune disease
- •Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with IM injections or blood draws
- •Asplenia, functional asplenia, or splenic excision
- •History of asthma, angioneurotic edema, diabetes or malignant tumour
- •History of thyroidectomy, or thyroid disease in last 12 months
- •Any acute infections in last 7 days
- •Any prior administration of immunodepressant or corticosteroids in last 6 months
- •Any prior administration of blood products in last 3 months
- •Any prior administration of other research vaccines or medicines in last 1 month
- •Any prior administration of attenuated live vaccine in last 15 days
- •Any prior administration of subunit or inactivated vaccines in last 7 days
- •Under the anti-TB prevention or therapy
- •Subjects with temperature >37.0°C on axillary setting
- •Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives
- •Exclusion Criteria for the second dose:
- •Subjects will not be eligible for the second dose if any of following adverse events happened after the first dose. They can continue other process of the study without the second dose vaccination according to the opinion of the investigator.
- •Had any serious adverse events related to the first dose of inactivated vaccine (vero cell) against EV71 within 7 days
- •Hypersensitivity reactions after vaccination (including urticaria/rashes that occur within 30 minutes after inoculation)
- •Anaphylaxis after vaccination
- •Any confirmed or suspected autoimmune disease or immune deficiency diseases, including human immunodeficiency virus (HIV) infection
- •Any condition that in the opinion of the investigator, or IRB
结局指标
主要结局
the incidence density of the EV71-associated diseases in the vaccine group and placebo group.
时间窗: begin at day 56 up to 14 months
compare the incidence density of the EV71-associated diseases between the vaccine group and placebo group in Chinese children aged 6-35 months.
次要结局
- the frequency of all the adverse events in vaccine group and placebo group.(up to 14 months)
- Seropositive rate of the vaccine group(14 months after first vaccination)
- Seroconversion rate of the vaccine group(14 months after first vaccination)
- GMT of the vaccine group(14 months after first vaccination)
- Seropositive rate of the vaccine group and placebo group(28 days after the second vaccination)
- Seroconversion rate of the vaccine group and placebo group(28 days after the second vaccination)
- GMT of the vaccine group and placebo group(28 days after the second vaccination)
- GMI of the vaccine group and placebo group(28 days after the second vaccination)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
2 期
Pleconaril Enteroviral Sepsis SyndromeEnterovirus InfectionNCT00031512National Institute of Allergy and Infectious Diseases (NIAID)61
已完成
2 期
A Phase II, Safety and Efficacy Study of Inactivated EV 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese InfantsThe Study Focused on the Safety of Inactivated EV71 Vaccine (Human Diploid Cell) Against Hand, Foot and Mouth Disease in Chinese Children and InfantsNCT01512706Institute of Medical Biology, Chinese Academy of Medical Sciences660
已完成
1 期
A Safety Study of Inactivated EV71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Adults, Children and InfantsHand, Foot and Mouth DiseaseNCT01391494Institute of Medical Biology, Chinese Academy of Medical Sciences288
Unknown
4 期
The Phase IVc of Inactivated Enterovirus 71 Vaccine (Human Diploid Cell)Hand, Foot and Mouth Disease (HFMD)NCT03240744Chinese Academy of Medical Sciences800
Unknown
4 期
The Phase IVd of Inactivated Enterovirus 71 VaccineHand, Foot and Mouth Disease (HFMD)NCT03296410Chinese Academy of Medical Sciences1,220